tobevibart
tobevibart: developed by 1 company · 2 clinical trials tracked.
tobevibart evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could tobevibart → VIR affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Vir Biotechnology, Inc. (VIR) Viral Hepatitis | Phase 3 |
Clinical Trials (2)
A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart+Elebsiran Combination Therapy in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (ECLIPSE 2)
Primary endpoint: HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24
A Phase 3 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Tobevibart + Elebsiran Combination Therapy in Participants With Chronic HDV Infection (ECLIPSE 1)
Primary endpoint: HDV RNA < Lower Limit of Quantification (LLOQ), Target Not Detected (TND) and alanine aminotransferase (ALT) normalization (ALT </= Upper Limit of Normal [ULN]) at Week 48 for Arm 1 vs at Week 12 for Arm 2
Frequently asked questions
Who is developing tobevibart?
tobevibart is being developed by Vir Biotechnology, Inc..
How many clinical trials involve tobevibart?
BioSniper tracks 2 clinical trials involving tobevibart.